Qlife, a first mover in clinical-grade home diagnostics, and its partner Hipro Biotechnology are advancing two additional biomarker tests—nt...
Towards a merger with a vision
Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) and Hipro Biotechnology Co.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...
Gothenburg, Sweden - Qlife Holding AB (“Qlife” or the “Company”) announces that it has finalized its clinical study for children and young p...
Qlife Holding AB ("Qlife" or the "Company") has entered into a non-binding letter of intent ("Letter of Intent") with Hipro Biotechnology Co...
Qlife Holding AB held its annual general meeting on 28 May 2025.
Qlife Holding AB höll den 28 maj 2025 årsstämma varvid i huvudsak följande beslut fattades.
Progress on all levels
Qlife Holding AB:s (“Qlife”) årsredovisning finns från och med idag tillgänglig på Qlifes hemsida: https://qlifeholding.
Qlife Holding AB's ("Qlife") Annual Report is available on Qlife's website: https://qlifeholding.
Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 28 maj 2025 kl.
Qlife is positioned at the forefront of the fast-growing at-home diagnostics market, offering lab-grade biomarker testing with global potent...
The Egoo Phe System, developed to measure phenylalanine (Phe) levels associated with the PKU condition, is now entering its final phase ahea...
Today, on 21 March 2025, an extraordinary general meeting was held in Qlife Holding AB.
Idag, den 21 mars 2025, hölls extra bolagsstämma i Qlife Holding AB.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Following a successful rights issue, Qlife has convened an extraordinary general meeting to expand its Board of Directors with three new mem...
Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, den 21 mars 2025 kl.
Qlife Holding AB, reg.no. 559224-8040 (the ”Company”), will hold an Extraordinary General Meeting on 21 March 2025 at.
Qlife is pleased to announce that, in collaboration with Hipro Biotechnology, the company has successfully verified biomarkers related to th...
Qlife is proud to announce a major expansion of Egoo.
Qlife is proud to announce the expansion of the Egoo.
Qlife Holding AB (publ) (“Qlife” or the “Company”) announces that members of the Company's Board of Directors and management, including CEO ...
Transition to a commercial business
The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information.
Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the...
The company is pleased to announce that Qlife, in collaboration with its strategic partner Hipro Biotechnology, has developed a new Egoo Hea...
Qlife provides sales and regulatory updates
Qlife provides update on operational progress in China
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, ...
Vid årsstämman den 26 juni 2024 valdes Göteborgs Revision Kommanditbolag (”Göteborgs Revision”) till revisionsbolag för Qlife Holding AB (pu...
Qlife announces outcome in directed issues
Today, on 8 November 2024, an extraordinary general meeting, and the second control meeting, was held in Qlife Holding AB.
Idag, den 8 november 2024, hölls extra bolagsstämma, tillika den andra kontrollstämman, i Qlife Holding AB.
Finally there
Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, tillika andra kontrollstämma, den 8 november...
Qlife Holding AB (publ) (“Qlife” or the “Company”) has decided to withdraw its proposal to change the Company’s name as the intended name, E...
Resent due to technical problems news distributor. Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and ...
Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals ...
Peter Warthoe, one of the three founders of Qlife, is back in his management role as Chief Scientific Officer and will focus on the company’...
Qlife Holding AB (publ) (“Qlife” or the “Company”) has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act (“ABL”), prep...
Qlife Holding AB (publ) (“Qlife” or the “Company”) recently announced a restructuring and new financing to support its strategic goals.
Qlife Holding AB (publ) ("Qlife" or the "Company") is pleased to announce a comprehensive business update in light of recent strategic devel...
Restructuring the company
Med anledning av sammanläggningen av aktier i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) som beslutades på årsstämman den 26 juni 202...
